Dr. Miron on Resistance Mechanisms to FGFR Inhibitors in Cholangiocarcinoma

Publication
Video
Supplements and Featured PublicationsNovel Therapeutic Approaches to Target FGFR Mutations in Solid Tumors
Volume 1
Issue 1

Benjamin Miron, MD, discusses mechanisms of resistance to FGFR inhibitors in cholangiocarcinoma.

Benjamin Miron, MD, fellow, Hematology/Oncology, Fox Chase Cancer Center, discusses mechanisms of resistance to FGFR inhibitors in cholangiocarcinoma.

Treatment with FGFR inhibitors can lead to the emergence of several mutations that promote resistance, Miron says. Although there is not much known about these mutations, data from the use of FGFR inhibitors in biliary cancers have shed some light on some resistance mechanisms, Miron explains. These resistance mutations are similar to those that have been observed with other TKIs, such as EGFR inhibitors, Miron adds.

There are currently no approved agents that can target resistance mechanisms to FGFR inhibitors; however, drugs are under development to fill this unmet need, Miron adds. Without approved drugs, the current standard for patients who develop such mutations during treatment with an FGFR inhibitor is to switch therapies or to enroll to a clinical trial, Miron concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD